We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Protective Antibodies for Rare, Polio-like Disease in Children Identified
News

Protective Antibodies for Rare, Polio-like Disease in Children Identified

Protective Antibodies for Rare, Polio-like Disease in Children Identified
News

Protective Antibodies for Rare, Polio-like Disease in Children Identified

Antibodies for respiratory virus that can cause a rare polio-like disease that causes paralysis in children have been identified by a team of researchers at Purdue University, Vanderbilt University Medical Center and the University of Wisconsin. The virus, enterovirus 68, has binding sites for the antibodies. The structural analysis of the virus shows that the antibody binding sites (shown here in gold and blue) do not overlap. Credit: Purdue University image/Richard Kuhn.
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Protective Antibodies for Rare, Polio-like Disease in Children Identified"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.

The illness, called acute flaccid myelitis (AFM), causes sudden weakness in the arms and legs following a fever or respiratory illness. More than 600 cases have been identified since the U.S. Centers for Disease Control and Prevention began tracking the disease in 2014.


There is no specific treatment for AFM, which tends to strike in the late summer or early fall and which has been associated with some deaths. However, the disease has recently been linked to a group of respiratory viruses called enterovirus D68 (EV-D68).


Researchers at the Vanderbilt Vaccine Center isolated antibody-producing blood cells from the blood of children who had previously been infected by EV-D68. By fusing the blood cells to fast-growing myeloma cells, the researchers were able to generate a panel of monoclonal antibodies that potently neutralized the virus in laboratory studies.


Colleagues at Purdue determined the structure of the antibodies, which shed light on how they specifically recognize and bind to EV-D68. One of the antibodies protected mice from respiratory and neurologic disease when given either before or after infection by the enterovirus.


The findings, published July 3 in the journal Science Immunology, suggest that these antibodies potentially could prevent EV-D68 infection and AFM in humans.


“We were excited to isolate potent human antibodies that inhibit this devastating polio-like virus, and these studies will form the basis for taking them forward to clinical trials,” said James Crowe, MD, director of the Vanderbilt Vaccine Center, Ann Scott Carell Professor of Pediatrics and Pathology, Microbiology and Immunology.


“Studying infectious disease from a very basic level and applying the results in an animal model of disease is very powerful; hopefully, our studies will translate to a future therapeutic for this disease in children,” said Richard Kuhn, PhD, Purdue’s Trent and Judith Anderson Distinguished Professor in Science; Krenicki Family Director, Purdue Institute of Inflammation, Immunology and Infectious Disease.

Reference
Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease. Matthew R. Vogt et al. Science Immunology  03 Jul 2020: Vol. 5, Issue 49, eaba4902, DOI: 10.1126/sciimmunol.aba4902.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement